Highlights Diamyd Medical AB

Equities

DMYD B

SE0005162880

Delayed Nasdaq Stockholm Other stock markets 04:16:23 2024-04-30 am EDT			5-day change	1st Jan Change
10.74 ^SEK	-2.36%		+11.88%	+63.47%

Apr. 18	Diamyd Medical Raises SEK57 Million in Rights Issue	MT
Apr. 12	Recruitment Milestone Reaches in Diamyd® Phase 3 Trial	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Diamyd Medical Raises SEK57 Million in Rights Issue	Apr. 18	MT
Recruitment Milestone Reaches in Diamyd® Phase 3 Trial	Apr. 12	CI
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Mar. 27	CI
Diamyd Medical to Present New Genetic Data at the ASIT Summit in Boston, MA	Feb. 29	CI
In-Depth Analysis of Diamyd Medical AB's Phase II Trial Further Supports Value of Presented Insulin Production	Jan. 24	CI
Diamyd Medical AB Reports Earnings Results for the First Quarter Ended November 30, 2023	Jan. 24	CI
Diamyd Medical S.A. Announces Interim Analysis of the Transformational Gene-Based Precision Medicine Phase 3 Trial, DIAGNODE-3, for Type 1 Diabetes Is Planned for July 2024	Jan. 04	CI
Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea	Dec. 06	CI
Diamyd Medical Partners With DiaUnion for Diabetes Drug Trial	Nov. 07	MT
Diamyd Medical Partners with Diamyd Medical to Recruit Participants for Type 1 Diabetes Prevention Trial	Nov. 07	CI
Diamyd Medical AB Announces Follow-Up Study Recommends Diamyd to Offer Advantages in Delivering Type 1 Diabetes Onset	23-10-26	CI
Diamyd Medical AB Announces Preliminary Results from Booster Trial with Diamyd Provide Additional Support for Intralymphatic Injection	23-10-20	CI
Diamyd Medical AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	23-10-11	CI
Diamyd Medical AB Reports Earnings Results for the Full Year Ended August 31, 2023	23-10-11	CI
Diamyd Medical AB Announces Registrational Phase III Trial in Type 1 Diabetes with Diamyd Expands to the US	23-09-05	CI
Diamyd Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-06-28	CI
Diamyd Medical AB Announces Topline Results from Remygen Trial in Individuals with Long-Term Type 1 Diabetes	23-05-10	CI
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-04-05	CI
Diamyd Medical AB Partners with JDRF to Advance the DIAGNODE-3 Phase 3 Trial in Type 1 Diabetes	23-04-04	CI
Diamyd Medical Announces That Patient Recruitment for the Single Pivotal Precision Medicine Phase 3 Trial DIAGNODE-3 Is Progressing According to Plan	23-02-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Diamyd Medical AB

Equities

DMYD B

SE0005162880

Highlights

Filters